HOUSE BILL 170

C3 1lr0975 (PRE–FILED)

By: **Delegate K. Young** Requested: October 14, 2020

Introduced and read first time: January 13, 2021 Assigned to: Health and Government Operations

A BILL ENTITLED

1 AN ACT concerning

2 Cancer Drugs – Physician Dispensing and Coverage

3 FOR the purpose of providing that certain provisions of law do not prohibit a physician who 4 has a valid dispensing permit and complies with certain provisions of law from 5 personally dispensing to a patient by mail or other commercial method a starter 6 dosage of a cancer drug or device or an initial or refill prescription of a cancer drug; 7 requiring certain entities to allow certain insureds, enrollees, and beneficiaries to 8 obtain a cancer drug from a dispensing physician; defining certain terms; requiring 9 that certain beneficiaries be allowed to obtain a cancer drug from a dispensing 10 physician; providing for the application of this Act; providing for a delayed effective date; and generally relating to cancer drugs. 11

12 BY adding to

19

13 Article – Health Occupations

14 Section 12–102(l)

15 Annotated Code of Maryland

16 (2014 Replacement Volume and 2020 Supplement)

17 BY repealing and reenacting, with amendments,

18 Article – Health Occupations

Section 12–102(l) and (m)

20 Annotated Code of Maryland

21 (2014 Replacement Volume and 2020 Supplement)

22 BY repealing and reenacting, with amendments,

23 Article – Insurance

24 Section 15–847(a) and (d) and 15–1611.1

25 Annotated Code of Maryland

26 (2017 Replacement Volume and 2020 Supplement)



$\frac{1}{2}$	SECTION 1. BE IT ENACTED BY THE GENERAL ASSEMBLY OF MARYLAND, That the Laws of Maryland read as follows:				
3	Article - Health Occupations				
4	12–102.				
5 6 7 8	DISPENSING PERMIT AND COMPLIES WITH SUBSECTION (C)(2)(II) OF THIS SECTION FROM PERSONALLY DISPENSING TO A PATIENT OR PATIENT OF THE PHYSICIAN'S				
9	(1) A STARTER DOSAGE OF A CANCER DRUG OR DEVICE; OR				
10	(2) AN INITIAL OR REFILL PRESCRIPTION OF A CANCER DRUG.				
11 12 13	[(1)] (M) The Board of Pharmacy, the Board of Dental Examiners, the Board of Physicians, and the Board of Podiatric Medical Examiners annually shall report to the Office of Controlled Substances Administration:				
14 15	(1) The names and addresses of its licensees who are authorized to personally prepare and dispense prescription drugs; and				
16 17 18	accordance with subsection (c)(2)(ii)4L of this section, that they have personally prepared				
19 20					
21	(1) Have the dispensing permit revoked; and				
22	(2) Be subject to disciplinary actions by the appropriate licensing board.				
23	Article – Insurance				
24	15–847.				
25	(a) (1) In this section the following words have the meanings indicated.				
26	(2) (I) "CANCER DRUG" MEANS ANY ORAL ONCOLOGY DRUG.				
27 28	(II) "CANCER DRUG" INCLUDES ANY ORAL ONCOLOGY SPECIALTY DRUG THAT IS PRESCRIBED FOR THE TREATMENT OF CANCER.				

"Complex or chronic medical condition" means a physical,

[(2)] **(3)**

29

(i)

1	behavioral, or developme	ental co	ondition that:		
2		1.	may have no known cure;		
3		2.	is progressive; or		
4 5	undertreated.	3.	can be debilitating or fatal if left untreated or		
6	(ii)	"Com	plex or chronic medical condition" includes:		
7		1.	multiple sclerosis;		
8		2.	hepatitis C; and		
9		3.	rheumatoid arthritis.		
10 11 12	STATE WHO HOLDS A VALID DISPENSING PERMIT UNDER TITLE 12, SUBTITLE 1 OF				
13 14 15 16	methods that an insurer, a nonprofit health service plan, or a health maintenance organization uses to review and preauthorize drugs prescribed by a health care provider				
17 18	[(4)] (6) affects fewer than:	(i)	"Rare medical condition" means a disease or condition that		
19		1.	200,000 individuals in the United States; or		
20		2.	approximately 1 in 1,500 individuals worldwide.		
21	(ii)	"Rare	e medical condition" includes:		
22		1.	cystic fibrosis;		
23		2.	hemophilia; and		
24		3.	multiple myeloma.		
25	[(5)] (7)	(i)	"Specialty drug" means a prescription drug that:		
26 27	medical condition or a ra	1. re med	is prescribed for an individual with a complex or chronic lical condition;		

1	2. costs \$600 or more for up to a 30-day supply;
2	3. is not typically stocked at retail pharmacies; and
3 4	4. A. requires a difficult or unusual process of delivery to the patient in the preparation, handling, storage, inventory, or distribution of the drug; or
5 6 7	B. requires enhanced patient education, management, or support, beyond those required for traditional dispensing, before or after administration of the drug.
8	(ii) "Specialty drug" does not include a prescription drug prescribed to treat diabetes, HIV, or AIDS.
10 11 12 13	(d) (1) Subject to § 15–805 of this subtitle [and], notwithstanding § 15–806 of this subtitle, AND EXCEPT AS PROVIDED IN PARAGRAPH (2) OF THIS SUBSECTION, nothing in this article or regulations adopted under this article precludes an entity subject to this section from requiring a covered specialty drug to be obtained through:
14 15	[(1)] (I) a designated pharmacy or other source authorized under the Health Occupations Article to dispense or administer prescription drugs; or
16 17	[(2)] (II) a pharmacy participating in the entity's provider network, if the entity determines that the pharmacy:
18	[(i)] 1. meets the entity's performance standards; and
19	[(ii)] 2. accepts the entity's network reimbursement rates.
20 21 22	(2) AN ENTITY SUBJECT TO THIS SECTION SHALL ALLOW AN INSURED OR ENROLLEE TO OBTAIN FROM A DISPENSING PHYSICIAN A COVERED SPECIALTY DRUG THAT IS A CANCER DRUG.
23	15–1611.1.
24 25	(A) IN THIS SECTION THE FOLLOWING WORDS HAVE THE MEANINGS INDICATED.
26 27	(1) "CANCER DRUG" HAS THE MEANING STATED IN § 15–847 OF THIS TITLE.
28 29 30	(2) "DISPENSING PHYSICIAN" MEANS A LICENSED PHYSICIAN IN THE STATE WHO HOLDS A VALID DISPENSING PERMIT UNDER TITLE 12, SUBTITLE 1 OF THE HEALTH OCCUPATIONS ARTICLE.

- [(a)] (B) Except as provided in subsection [(b)] (C) of this section, a pharmacy benefits manager may not require that a beneficiary use a specific pharmacy or entity to fill a prescription if:
- 4 (1) the pharmacy benefits manager or a corporate affiliate of the pharmacy 5 benefits manager has an ownership interest in the pharmacy or entity; or
- 6 (2) the pharmacy or entity has an ownership interest in the pharmacy 5 benefits manager or a corporate affiliate of the pharmacy benefits manager.
- 8 [(b)] (C) (1) [A] EXCEPT AS PROVIDED IN PARAGRAPH (2) OF THIS 9 SUBSECTION, A pharmacy benefits manager may require a beneficiary to use a specific pharmacy or entity for a specialty drug as defined in § 15–847 of this title.
- 11 (2) A BENEFICIARY SHALL BE ALLOWED TO OBTAIN A CANCER DRUG 12 FROM A DISPENSING PHYSICIAN.
- SECTION 2. AND BE IT FURTHER ENACTED, That this Act shall apply to all policies, contracts, and health benefit plans issued, delivered, or renewed in the State on or after January 1, 2022.
- SECTION 3. AND BE IT FURTHER ENACTED, That this Act shall take effect January 1, 2022.